"Kirkland & Ellis Advises on Major Spin-Off IPO of Xuanzhu Biopharmaceutical Co. in Hong Kong"

"Kirkland & Ellis advised Sihuan Pharmaceutical Holdings Group Ltd. on the spin-off and IPO of its subsidiary, Xuanzhu Biopharmaceutical Co., Ltd., which is now listed on the Hong Kong Stock Exchange. This IPO is notable as the largest biotech spin-off under Hong Kong's Chapter 18A in three years and the first since new filing regulations were introduced by the China Securities Regulatory Commission. Xuanzhu Biopharm focuses on the R&D and commercialization of innovative drugs, particularly in digestive diseases, oncology, and non-alcoholic steatohepatitis."

Kirkland & Ellis represented Sihuan Pharmaceutical Holdings Group Ltd. and Xuanzhu Biopharmaceutical Co., Ltd. in a significant transaction involving the spin-off, global offering, and separate listing of Xuanzhu Biopharm on the Main Board of the Hong Kong Stock Exchange. This transaction marks the largest spin-off listing of a biotech company under Chapter 18A of the Hong Kong Listing Rules in the past three years and is the first of its kind since the introduction of the new filing regulations by the China Securities Regulatory Commission. Xuanzhu Biopharm is an innovative company focused on the research, development, production, and commercialization of innovative drugs, with a dual-track R&D system targeting digestive diseases, oncology, and non-alcoholic steatohepatitis (NASH). The Kirkland team involved in this transaction included capital markets lawyers Mengyu Lu, Samantha Peng, George Zheng, Yuchen Han, Chuanwen Wang, Derek Zheng, and Wanli Ma.

"Kirkland & Ellis Advises on Major Spin-Off IPO of Xuanzhu Biopharmaceutical Co. in Hong Kong"

Read the full story

Cookie Preferences

Strictly Necessary

Analytics & Statistics

Marketing & Ads